Israel: A Life Sciences Overview

Israel’s Life Sciences Sector in 2025: Resilient Innovation Across Healthcare, Biotech, Pharma and Health Tech

Israel’s life sciences sector entered 2025 with a familiar duality: world-class scientific and clinical innovation, set against continued geopolitical and macroeconomic uncertainty. 

Impact of war

Conflict has had a two-sided impact on the sector. Operationally, many companies and hospitals experienced disruptions from reserve duty call-ups, logistical constraints and clinical capacity pressures, with some trials and commercial rollouts slowed or reprioritised. At the same time, the security environment accelerated demand (in Israel and abroad) for solutions that improve system resilience – including remote care, hospital-at-home models, mental health support, trauma and rehabilitation technologies, and cybersecurity for clinical environments. A ceasefire framework in the Gaza Strip has enabled the demobilisation of reservists and created optimism for 2026.  At the time of publication, regional confrontation involving Iran has added a further layer of uncertainty for cross-border activity, even as the sector has continued to operate and innovate.

Sector strengths

Despite geopolitical unrest and a challenging funding environment, the sector remained an engine for growth in 2025, anchored by strong academic research, hospital-based clinical capabilities and a dense network of venture-backed companies. Advanced hospital systems and centralised health records support rapid clinical validation and real-world evidence generation, while universities and research institutes feed a steady pipeline of translational research into startups and spinouts. An additional area of momentum is bioconvergence – the combination of life sciences with engineering disciplines such as AI, data science, materials, robotics and microelectronics. In Israel, bioconvergence is increasingly visible in next-generation diagnostics, lab automation, computational drug discovery and engineering-led approaches to biologics and medical devices, leveraging the country’s cross-disciplinary talent base and its strengths in software and hardware.

Healthcare

Israel’s healthcare system continues to function as both a national asset and an innovation platform. Providers and health funds remain relatively early adopters of digital tools that improve access, triage and chronic disease management, and the country’s longitudinal datasets make Israel a strong environment for outcome-driven validation. In 2025, a key trend in healthcare innovation remained the operationalisation of AI – not only in imaging and diagnostics, but also in workflow optimisation, patient engagement and population health analytics.

Health tech 

Health tech continued to stand out in 2025 for transaction activity. Deal volume was reported as the highest among tracked tech verticals (reported at 179 rounds), reflecting sustained investor interest in scalable, software-centric models even as capital allocation became more concentrated.

Within health tech, much of the market focus continues to cluster around:

• AI-enabled clinical decision support and imaging workflows;
• remote monitoring and hybrid care models, especially for chronic conditions;
• cybersecurity and privacy solutions tailored to clinical environments and medical devices; and
• data infrastructure, interoperability and real-world evidence platforms serving providers, payors and pharma.

Biotech and Pharma  

Israel’s biotech segment remains research-intensive and increasingly international in its go-to-market and funding strategies. In 2025, the sector continued to benefit from strong scientific talent and the ability to generate assets in oncology, immunology, neurology and rare disease, as well as enabling platforms (including biologics engineering and advanced analytics for drug development). However, the global funding environment continued to reward later-stage clarity: robust preclinical packages, early clinical signals, and credible regulatory and manufacturing plans. As a result, many biotech companies pursued milestone-based financings, strategic collaborations and licensing pathways earlier in the lifecycle. 

Israel's pharmaceutical sector is smaller and more specialised than in larger jurisdictions, but it can be strategically relevant – particularly in areas such as complex generics, formulation and specialty manufacturing, and in enabling collaborations that commercialise Israeli-originated innovation through global channels.

Regulatory Snapshot 

On the regulatory front, Israel is shifting from policy to implementation.

• The Medical Information Mobilization Law (2024) and the Fast Healthcare Interoperability Resources (FHIR)-based certification programme promulgated by the Ministry of Health (MOH) are intended to operationalise interoperability and patient-centered data sharing.
• New MOH principles (Feb 2026) guide AI-based interventional trials around safety, privacy, fairness, transparency and human oversight.
• The MOH Medical Equipment Division (AMAR) remains pivotal for device lifecycle access, and the MOH maintains oversight of drug registration and clinical trials. The overall direction is an ecosystem that seeks to combine innovation-friendly infrastructure with clearer guardrails, supportive of personalised and preventive care.
• In March 2025 the MOH unveiled an outline that materially shortens registration timelines for original, biosimilar and generic medicines - down to 70 or 120 business days where criteria are met. The framework prioritises products addressing urgent population needs. The outline is being piloted in 2025–2026, signaling an increased reliance on trusted foreign approvals, combined with strong quality, safety and pharmacovigilance documentation.
• The Cabinet‑approved National Digital Health Plan (2018) still frames the system’s trajectory toward data‑driven, interoperable care and innovation. That plan explicitly envisaged regulatory changes to enable data‑based research and innovation – a trajectory now visible in the Medical Information Mobilization Law and MOH’s certification work.

Outlook for 2026

Looking ahead,geopolitical developments are expected to remain part of the operating backdrop in 2026. Health tech is likely to remain active given its capital efficiency and speed to market, while biotech and pharma-facing innovation will continue to depend on disciplined financing and the ability to attract global partners. Overall, Israel’s life sciences sector enters 2026 with strong fundamentals – deep scientific talent, high-quality clinical environments and continued entrepreneurial activity – while operating in a challenging funding market.